| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney | 23 | 2023 | 155 | 3.800 |
Why?
|
| Kidney Diseases | 15 | 2014 | 100 | 2.570 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 21 | 2012 | 34 | 2.370 |
Why?
|
| Lupus Nephritis | 16 | 2019 | 29 | 2.190 |
Why?
|
| Peritoneal Dialysis | 17 | 2011 | 23 | 1.820 |
Why?
|
| Biopsy, Needle | 9 | 2021 | 96 | 1.820 |
Why?
|
| Kidney Failure, Chronic | 22 | 2012 | 151 | 1.290 |
Why?
|
| Biopsy | 14 | 2018 | 199 | 1.210 |
Why?
|
| Nephrology | 4 | 2018 | 12 | 1.170 |
Why?
|
| Prognosis | 25 | 2023 | 750 | 1.160 |
Why?
|
| Proteinuria | 12 | 2019 | 57 | 1.150 |
Why?
|
| Peritoneal Dialysis, Continuous Ambulatory | 12 | 2002 | 13 | 1.130 |
Why?
|
| Glomerulonephritis | 12 | 2007 | 20 | 1.130 |
Why?
|
| Kidney Glomerulus | 19 | 2023 | 47 | 1.100 |
Why?
|
| Humans | 111 | 2023 | 26025 | 1.000 |
Why?
|
| Adult | 69 | 2021 | 7363 | 0.980 |
Why?
|
| Glomerulonephritis, IGA | 3 | 2023 | 8 | 0.980 |
Why?
|
| Creatinine | 13 | 2019 | 45 | 0.820 |
Why?
|
| Peritonitis | 7 | 2002 | 16 | 0.800 |
Why?
|
| Male | 64 | 2021 | 14008 | 0.790 |
Why?
|
| Nephrosis, Lipoid | 5 | 2019 | 10 | 0.790 |
Why?
|
| Middle Aged | 50 | 2021 | 8507 | 0.780 |
Why?
|
| Needles | 2 | 2021 | 19 | 0.780 |
Why?
|
| Renal Dialysis | 9 | 2012 | 107 | 0.770 |
Why?
|
| Hematuria | 6 | 2014 | 14 | 0.750 |
Why?
|
| Acute Kidney Injury | 4 | 2019 | 40 | 0.720 |
Why?
|
| Steroids | 6 | 2012 | 23 | 0.720 |
Why?
|
| Female | 66 | 2021 | 14397 | 0.710 |
Why?
|
| Nephrotic Syndrome | 8 | 2019 | 25 | 0.670 |
Why?
|
| Nephrologists | 1 | 2018 | 3 | 0.630 |
Why?
|
| Immunosuppressive Agents | 8 | 2023 | 122 | 0.630 |
Why?
|
| Radiologists | 1 | 2018 | 6 | 0.630 |
Why?
|
| Scleroderma, Limited | 1 | 2018 | 3 | 0.630 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2019 | 87 | 0.580 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 104 | 0.580 |
Why?
|
| Prospective Studies | 10 | 2021 | 1659 | 0.550 |
Why?
|
| Clinical Competence | 2 | 2018 | 211 | 0.520 |
Why?
|
| Cystatin C | 1 | 2015 | 3 | 0.500 |
Why?
|
| Automation | 1 | 2014 | 8 | 0.480 |
Why?
|
| Image-Guided Biopsy | 1 | 2014 | 32 | 0.470 |
Why?
|
| Education, Medical, Continuing | 1 | 2014 | 34 | 0.450 |
Why?
|
| Plasmapheresis | 6 | 2013 | 12 | 0.390 |
Why?
|
| Eosinophilia | 3 | 2011 | 35 | 0.390 |
Why?
|
| Renal Insufficiency | 3 | 2006 | 13 | 0.390 |
Why?
|
| Follow-Up Studies | 13 | 2014 | 1712 | 0.380 |
Why?
|
| Dermatitis, Allergic Contact | 1 | 2011 | 4 | 0.380 |
Why?
|
| Pruritus | 1 | 2011 | 9 | 0.380 |
Why?
|
| Time Factors | 7 | 2018 | 1365 | 0.380 |
Why?
|
| Silicones | 1 | 2011 | 9 | 0.380 |
Why?
|
| Catheters, Indwelling | 1 | 2011 | 22 | 0.370 |
Why?
|
| Severity of Illness Index | 7 | 2019 | 930 | 0.370 |
Why?
|
| Internship and Residency | 2 | 2014 | 206 | 0.370 |
Why?
|
| Prednisone | 10 | 2019 | 61 | 0.360 |
Why?
|
| Reproducibility of Results | 5 | 2021 | 670 | 0.350 |
Why?
|
| Glomerular Filtration Rate | 5 | 2015 | 51 | 0.350 |
Why?
|
| Retrospective Studies | 19 | 2023 | 3297 | 0.340 |
Why?
|
| Lupus Erythematosus, Systemic | 6 | 1999 | 189 | 0.340 |
Why?
|
| Aged | 25 | 2021 | 8704 | 0.330 |
Why?
|
| Peritoneum | 6 | 2000 | 15 | 0.320 |
Why?
|
| Remission Induction | 6 | 2013 | 88 | 0.320 |
Why?
|
| Recurrence | 6 | 2019 | 306 | 0.320 |
Why?
|
| Amyloid Neuropathies, Familial | 1 | 2008 | 3 | 0.300 |
Why?
|
| Ultrasonography, Interventional | 3 | 2018 | 64 | 0.300 |
Why?
|
| Survival Rate | 9 | 2013 | 321 | 0.300 |
Why?
|
| Bacterial Infections | 2 | 2000 | 49 | 0.300 |
Why?
|
| Equipment Design | 2 | 2021 | 141 | 0.290 |
Why?
|
| AIDS-Associated Nephropathy | 4 | 2011 | 7 | 0.290 |
Why?
|
| Anemia | 4 | 1995 | 93 | 0.290 |
Why?
|
| Adolescent | 10 | 2014 | 2064 | 0.270 |
Why?
|
| Multiple Myeloma | 1 | 2006 | 21 | 0.270 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2003 | 24 | 0.260 |
Why?
|
| Anti-Inflammatory Agents | 4 | 2019 | 75 | 0.260 |
Why?
|
| Cyclosporins | 2 | 1998 | 3 | 0.250 |
Why?
|
| Hemorrhage | 4 | 2009 | 75 | 0.240 |
Why?
|
| Erythropoietin | 4 | 1995 | 48 | 0.240 |
Why?
|
| Hematoma | 3 | 2009 | 15 | 0.240 |
Why?
|
| Kidney Transplantation | 4 | 1994 | 120 | 0.230 |
Why?
|
| Young Adult | 7 | 2014 | 1853 | 0.220 |
Why?
|
| Methylprednisolone | 1 | 2003 | 20 | 0.210 |
Why?
|
| Aged, 80 and over | 11 | 2014 | 4659 | 0.200 |
Why?
|
| Renal Replacement Therapy | 2 | 2019 | 22 | 0.200 |
Why?
|
| Ultrasonography | 3 | 2014 | 222 | 0.200 |
Why?
|
| Multivariate Analysis | 5 | 2019 | 295 | 0.200 |
Why?
|
| Nephrosis | 3 | 2004 | 4 | 0.200 |
Why?
|
| Urban Population | 2 | 2000 | 143 | 0.200 |
Why?
|
| Risk Factors | 11 | 2011 | 2243 | 0.200 |
Why?
|
| Hypertension | 4 | 2018 | 217 | 0.190 |
Why?
|
| Ethylene Glycol | 1 | 2001 | 3 | 0.190 |
Why?
|
| Antidotes | 1 | 2001 | 3 | 0.190 |
Why?
|
| Mycoses | 1 | 2000 | 22 | 0.180 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2000 | 3 | 0.170 |
Why?
|
| Polycystic Kidney Diseases | 1 | 2000 | 4 | 0.170 |
Why?
|
| Pyrazoles | 1 | 2001 | 55 | 0.170 |
Why?
|
| Survival Analysis | 6 | 2007 | 235 | 0.170 |
Why?
|
| Child | 9 | 2009 | 1228 | 0.170 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2000 | 35 | 0.170 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2000 | 40 | 0.170 |
Why?
|
| Dialysis Solutions | 2 | 1998 | 5 | 0.160 |
Why?
|
| Kidney Neoplasms | 1 | 2000 | 66 | 0.160 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 1998 | 100 | 0.160 |
Why?
|
| Immune Complex Diseases | 2 | 1992 | 2 | 0.160 |
Why?
|
| Amlodipine | 1 | 2018 | 3 | 0.160 |
Why?
|
| Lisinopril | 1 | 2018 | 3 | 0.160 |
Why?
|
| Labetalol | 1 | 2018 | 5 | 0.160 |
Why?
|
| Nicardipine | 1 | 2018 | 4 | 0.160 |
Why?
|
| Prevalence | 4 | 2003 | 433 | 0.150 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 37 | 0.150 |
Why?
|
| Vasculitis | 3 | 2005 | 26 | 0.150 |
Why?
|
| Antihypertensive Agents | 1 | 2018 | 70 | 0.150 |
Why?
|
| Treatment Outcome | 10 | 2010 | 3292 | 0.140 |
Why?
|
| Hemofiltration | 2 | 1995 | 8 | 0.140 |
Why?
|
| Lung Diseases | 2 | 2005 | 42 | 0.140 |
Why?
|
| Glycation End Products, Advanced | 2 | 1994 | 7 | 0.140 |
Why?
|
| Urban Health | 2 | 1995 | 21 | 0.140 |
Why?
|
| Logistic Models | 2 | 2014 | 362 | 0.140 |
Why?
|
| Drug Resistance | 2 | 2012 | 42 | 0.130 |
Why?
|
| Liver Transplantation | 2 | 1995 | 65 | 0.130 |
Why?
|
| Biomarkers | 1 | 2019 | 549 | 0.130 |
Why?
|
| Liver Failure | 1 | 1995 | 8 | 0.120 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 2 | 1996 | 5 | 0.120 |
Why?
|
| Actin Cytoskeleton | 1 | 1994 | 7 | 0.120 |
Why?
|
| Disease Progression | 4 | 2011 | 685 | 0.120 |
Why?
|
| Pregnancy Complications | 2 | 2005 | 48 | 0.120 |
Why?
|
| Ultrafiltration | 3 | 2000 | 4 | 0.120 |
Why?
|
| Blood Pressure Determination | 1 | 1994 | 14 | 0.110 |
Why?
|
| Thrombosis | 2 | 1993 | 51 | 0.110 |
Why?
|
| Peritoneal Diseases | 2 | 1998 | 4 | 0.110 |
Why?
|
| Immunoglobulin G | 2 | 2009 | 87 | 0.110 |
Why?
|
| Hematocrit | 2 | 1995 | 13 | 0.110 |
Why?
|
| Blood Pressure | 1 | 1994 | 194 | 0.100 |
Why?
|
| Phosphorus | 1 | 2012 | 6 | 0.100 |
Why?
|
| Chelating Agents | 1 | 2012 | 12 | 0.100 |
Why?
|
| Ferric Compounds | 1 | 2012 | 8 | 0.100 |
Why?
|
| Diabetes Mellitus | 1 | 1993 | 126 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2008 | 272 | 0.100 |
Why?
|
| Apolipoproteins | 1 | 2011 | 7 | 0.100 |
Why?
|
| Lipoproteins, HDL | 1 | 2011 | 21 | 0.100 |
Why?
|
| Renal Artery Obstruction | 1 | 1991 | 2 | 0.090 |
Why?
|
| Patch Tests | 1 | 2011 | 2 | 0.090 |
Why?
|
| Exanthema | 1 | 2011 | 12 | 0.090 |
Why?
|
| Anti-Glomerular Basement Membrane Disease | 1 | 1989 | 1 | 0.080 |
Why?
|
| Endocarditis, Bacterial | 1 | 1989 | 5 | 0.080 |
Why?
|
| Case-Control Studies | 4 | 2011 | 550 | 0.080 |
Why?
|
| Amyloidosis | 2 | 2006 | 26 | 0.080 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 2 | 2009 | 9 | 0.080 |
Why?
|
| Diet | 1 | 2010 | 169 | 0.080 |
Why?
|
| Mutation | 2 | 2007 | 311 | 0.080 |
Why?
|
| Molecular Motor Proteins | 1 | 2008 | 1 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2008 | 10 | 0.080 |
Why?
|
| Hypertension, Renal | 2 | 2002 | 3 | 0.080 |
Why?
|
| Myosin Heavy Chains | 1 | 2008 | 7 | 0.080 |
Why?
|
| Treatment Failure | 2 | 2002 | 148 | 0.080 |
Why?
|
| Hemolysis | 1 | 2008 | 4 | 0.080 |
Why?
|
| Haplotypes | 1 | 2008 | 54 | 0.080 |
Why?
|
| Poisson Distribution | 2 | 2000 | 22 | 0.080 |
Why?
|
| Heart Valve Prosthesis | 1 | 2008 | 10 | 0.080 |
Why?
|
| Mitral Valve | 1 | 2008 | 9 | 0.080 |
Why?
|
| Aortic Valve | 1 | 2008 | 21 | 0.080 |
Why?
|
| Age Factors | 3 | 2019 | 744 | 0.080 |
Why?
|
| Vascular Diseases | 1 | 2008 | 43 | 0.070 |
Why?
|
| Lipoproteins | 1 | 2007 | 7 | 0.070 |
Why?
|
| Apolipoprotein E2 | 1 | 2007 | 12 | 0.070 |
Why?
|
| Mutation, Missense | 1 | 2007 | 21 | 0.070 |
Why?
|
| Glomerulonephritis, Membranous | 3 | 2001 | 6 | 0.070 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2007 | 45 | 0.070 |
Why?
|
| Genotype | 4 | 2011 | 335 | 0.070 |
Why?
|
| Skilled Nursing Facilities | 1 | 2007 | 23 | 0.070 |
Why?
|
| Patient Compliance | 2 | 2000 | 145 | 0.070 |
Why?
|
| Nursing Homes | 1 | 2007 | 33 | 0.070 |
Why?
|
| Membrane Proteins | 1 | 2007 | 151 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2008 | 373 | 0.070 |
Why?
|
| Staphylococcus epidermidis | 2 | 1996 | 4 | 0.070 |
Why?
|
| Autoantibodies | 1 | 2006 | 71 | 0.070 |
Why?
|
| Anemia, Pernicious | 1 | 1986 | 1 | 0.070 |
Why?
|
| Biological Transport | 2 | 1998 | 39 | 0.060 |
Why?
|
| Immunity, Maternally-Acquired | 1 | 2005 | 2 | 0.060 |
Why?
|
| Pedigree | 2 | 2007 | 55 | 0.060 |
Why?
|
| Isoantibodies | 1 | 2005 | 8 | 0.060 |
Why?
|
| Genes, Wilms Tumor | 1 | 2005 | 1 | 0.060 |
Why?
|
| Population | 1 | 2005 | 4 | 0.060 |
Why?
|
| Diabetes Insipidus | 1 | 1985 | 1 | 0.060 |
Why?
|
| Chicago | 2 | 1999 | 844 | 0.060 |
Why?
|
| Analysis of Variance | 2 | 1996 | 253 | 0.060 |
Why?
|
| Laryngeal Diseases | 1 | 1984 | 3 | 0.060 |
Why?
|
| Ambulatory Care | 2 | 1996 | 68 | 0.060 |
Why?
|
| Blood Transfusion | 3 | 1996 | 64 | 0.060 |
Why?
|
| Coronary Disease | 1 | 1984 | 51 | 0.060 |
Why?
|
| Staphylococcal Infections | 2 | 1996 | 151 | 0.060 |
Why?
|
| Algorithms | 1 | 2006 | 358 | 0.060 |
Why?
|
| Cyclophosphamide | 3 | 2010 | 49 | 0.060 |
Why?
|
| Nephrons | 1 | 2003 | 5 | 0.050 |
Why?
|
| Predictive Value of Tests | 3 | 2019 | 457 | 0.050 |
Why?
|
| Diabetic Nephropathies | 2 | 1994 | 22 | 0.050 |
Why?
|
| Educational Status | 2 | 1995 | 287 | 0.050 |
Why?
|
| Contraindications | 1 | 2002 | 32 | 0.050 |
Why?
|
| Radiography, Interventional | 1 | 2002 | 21 | 0.050 |
Why?
|
| Immunoglobulins | 2 | 1992 | 20 | 0.050 |
Why?
|
| Suicide, Attempted | 1 | 2001 | 12 | 0.050 |
Why?
|
| New York City | 1 | 2000 | 14 | 0.050 |
Why?
|
| Complement C3 | 3 | 1990 | 5 | 0.040 |
Why?
|
| Incidence | 3 | 2000 | 713 | 0.040 |
Why?
|
| Urea | 2 | 1996 | 10 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2000 | 74 | 0.040 |
Why?
|
| Age of Onset | 2 | 2011 | 91 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2002 | 412 | 0.040 |
Why?
|
| Clinical Trials as Topic | 2 | 2019 | 215 | 0.040 |
Why?
|
| Curriculum | 1 | 2000 | 142 | 0.040 |
Why?
|
| Forecasting | 2 | 1996 | 91 | 0.040 |
Why?
|
| Sclerosis | 1 | 1999 | 66 | 0.040 |
Why?
|
| Capillary Action | 1 | 1998 | 1 | 0.040 |
Why?
|
| Lymph | 1 | 1998 | 1 | 0.040 |
Why?
|
| Fluid Shifts | 1 | 1998 | 1 | 0.040 |
Why?
|
| Glycosylation | 1 | 1998 | 15 | 0.040 |
Why?
|
| Treatment Refusal | 1 | 1998 | 11 | 0.040 |
Why?
|
| Tissue Adhesions | 1 | 1998 | 12 | 0.040 |
Why?
|
| Microtubules | 2 | 1991 | 28 | 0.040 |
Why?
|
| Water | 1 | 1998 | 29 | 0.040 |
Why?
|
| Catheterization | 1 | 1998 | 41 | 0.040 |
Why?
|
| Genetic Variation | 2 | 2011 | 96 | 0.040 |
Why?
|
| Edema | 2 | 1996 | 24 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 326 | 0.040 |
Why?
|
| Microscopy, Electron | 3 | 2002 | 65 | 0.040 |
Why?
|
| Syndrome | 2 | 2005 | 73 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 1340 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2019 | 325 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2002 | 342 | 0.030 |
Why?
|
| United States | 4 | 2011 | 1981 | 0.030 |
Why?
|
| Child, Preschool | 1 | 1998 | 589 | 0.030 |
Why?
|
| Iron | 2 | 2012 | 21 | 0.030 |
Why?
|
| Ciprofloxacin | 1 | 1995 | 12 | 0.030 |
Why?
|
| Weight Gain | 1 | 1996 | 61 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 1996 | 290 | 0.030 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 1995 | 22 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 1995 | 133 | 0.030 |
Why?
|
| Sepsis | 1 | 1996 | 138 | 0.030 |
Why?
|
| Sex Factors | 1 | 1996 | 442 | 0.030 |
Why?
|
| Uremia | 1 | 1994 | 1 | 0.030 |
Why?
|
| Double-Blind Method | 2 | 1995 | 399 | 0.030 |
Why?
|
| Risk Assessment | 1 | 1996 | 622 | 0.030 |
Why?
|
| Hypertrophy | 1 | 1993 | 19 | 0.030 |
Why?
|
| Pregnancy | 2 | 2005 | 309 | 0.030 |
Why?
|
| Canada | 3 | 2000 | 49 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1993 | 91 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 1994 | 73 | 0.030 |
Why?
|
| Postoperative Complications | 2 | 1991 | 860 | 0.030 |
Why?
|
| Regression Analysis | 1 | 1994 | 252 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 1995 | 200 | 0.030 |
Why?
|
| Chronic Kidney Disease-Mineral and Bone Disorder | 1 | 2012 | 3 | 0.030 |
Why?
|
| Color | 1 | 2012 | 5 | 0.030 |
Why?
|
| Ferritins | 1 | 2012 | 8 | 0.030 |
Why?
|
| Constipation | 1 | 2012 | 18 | 0.030 |
Why?
|
| Complement System Proteins | 1 | 1992 | 8 | 0.030 |
Why?
|
| Substance Abuse, Intravenous | 1 | 1992 | 9 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 1992 | 30 | 0.030 |
Why?
|
| Seizures | 1 | 1993 | 63 | 0.030 |
Why?
|
| Feces | 1 | 2012 | 105 | 0.030 |
Why?
|
| Quality of Life | 2 | 1996 | 609 | 0.020 |
Why?
|
| Human Genome Project | 1 | 2011 | 1 | 0.020 |
Why?
|
| HapMap Project | 1 | 2011 | 1 | 0.020 |
Why?
|
| Apolipoprotein L1 | 1 | 2011 | 6 | 0.020 |
Why?
|
| Nephritis, Interstitial | 2 | 1995 | 7 | 0.020 |
Why?
|
| Renal Artery | 1 | 1991 | 6 | 0.020 |
Why?
|
| Crystallization | 1 | 1991 | 4 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 161 | 0.020 |
Why?
|
| Circadian Rhythm | 1 | 1994 | 231 | 0.020 |
Why?
|
| Neoplasms | 1 | 1993 | 219 | 0.020 |
Why?
|
| Graft Rejection | 1 | 1990 | 63 | 0.020 |
Why?
|
| Cryoglobulinemia | 1 | 1989 | 1 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 1989 | 25 | 0.020 |
Why?
|
| Hemodynamics | 1 | 1989 | 61 | 0.020 |
Why?
|
| Acute Disease | 1 | 1989 | 189 | 0.020 |
Why?
|
| Lod Score | 1 | 2008 | 12 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2008 | 26 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 2008 | 32 | 0.020 |
Why?
|
| DNA Primers | 1 | 2008 | 45 | 0.020 |
Why?
|
| Lung | 1 | 1989 | 155 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2009 | 1823 | 0.020 |
Why?
|
| Genome, Human | 1 | 2008 | 41 | 0.020 |
Why?
|
| Remission, Spontaneous | 1 | 1988 | 8 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2007 | 100 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 1991 | 333 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2012 | 1068 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2009 | 485 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2007 | 170 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2007 | 62 | 0.020 |
Why?
|
| Arteriosclerosis | 1 | 1987 | 9 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2007 | 56 | 0.020 |
Why?
|
| Animals | 1 | 1994 | 3389 | 0.020 |
Why?
|
| Prescriptions | 2 | 1996 | 17 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 2 | 1996 | 52 | 0.020 |
Why?
|
| Clinical Protocols | 2 | 1996 | 55 | 0.020 |
Why?
|
| Intrinsic Factor | 1 | 1986 | 1 | 0.020 |
Why?
|
| Schilling Test | 1 | 1986 | 1 | 0.020 |
Why?
|
| Antibodies | 1 | 1986 | 41 | 0.020 |
Why?
|
| Cryoglobulins | 1 | 1985 | 1 | 0.020 |
Why?
|
| Glomerular Mesangium | 1 | 1985 | 3 | 0.020 |
Why?
|
| Basement Membrane | 1 | 1985 | 11 | 0.020 |
Why?
|
| Hemoglobins | 1 | 1986 | 74 | 0.020 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2005 | 6 | 0.020 |
Why?
|
| Peroxidase | 1 | 2005 | 16 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 1985 | 73 | 0.020 |
Why?
|
| Fetal Blood | 1 | 2005 | 13 | 0.020 |
Why?
|
| Denys-Drash Syndrome | 1 | 2005 | 1 | 0.020 |
Why?
|
| Frasier Syndrome | 1 | 2005 | 1 | 0.020 |
Why?
|
| Autoantigens | 1 | 2005 | 23 | 0.020 |
Why?
|
| Kidney Concentrating Ability | 1 | 1985 | 1 | 0.020 |
Why?
|
| Cesarean Section | 1 | 2005 | 28 | 0.020 |
Why?
|
| Vasopressins | 1 | 1985 | 6 | 0.020 |
Why?
|
| Exons | 1 | 2005 | 30 | 0.020 |
Why?
|
| Pre-Eclampsia | 1 | 1985 | 7 | 0.020 |
Why?
|
| Antigen-Antibody Complex | 1 | 2004 | 6 | 0.020 |
Why?
|
| Emergencies | 1 | 2005 | 33 | 0.020 |
Why?
|
| Eosinophils | 1 | 1985 | 42 | 0.020 |
Why?
|
| Capillaries | 1 | 2004 | 11 | 0.020 |
Why?
|
| Dyspnea | 1 | 2005 | 37 | 0.020 |
Why?
|
| Airway Obstruction | 1 | 1984 | 17 | 0.010 |
Why?
|
| Cyclosporine | 1 | 2004 | 11 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2005 | 77 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 2 | 1996 | 291 | 0.010 |
Why?
|
| Phenotype | 1 | 2005 | 290 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 1984 | 134 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2005 | 587 | 0.010 |
Why?
|
| World Health Organization | 1 | 2001 | 11 | 0.010 |
Why?
|
| International Cooperation | 1 | 2000 | 22 | 0.010 |
Why?
|
| Osmotic Pressure | 1 | 2000 | 5 | 0.010 |
Why?
|
| Water-Electrolyte Balance | 1 | 2000 | 4 | 0.010 |
Why?
|
| Demography | 1 | 2000 | 71 | 0.010 |
Why?
|
| Guidelines as Topic | 1 | 2000 | 62 | 0.010 |
Why?
|
| Minority Groups | 1 | 2000 | 70 | 0.010 |
Why?
|
| Body Surface Area | 1 | 1996 | 3 | 0.010 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 1996 | 4 | 0.010 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 1996 | 5 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 1996 | 34 | 0.010 |
Why?
|
| Nutritional Status | 1 | 1996 | 48 | 0.010 |
Why?
|
| Permeability | 1 | 1996 | 116 | 0.010 |
Why?
|
| Leukocyte Count | 2 | 1987 | 64 | 0.010 |
Why?
|
| Social Environment | 1 | 1996 | 78 | 0.010 |
Why?
|
| Necrosis | 1 | 1995 | 26 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 1995 | 22 | 0.010 |
Why?
|
| Life Style | 1 | 1996 | 189 | 0.010 |
Why?
|
| Erythrocyte Transfusion | 1 | 1995 | 13 | 0.010 |
Why?
|
| Epithelium | 1 | 1989 | 23 | 0.010 |
Why?
|
| Complement C4 | 1 | 1987 | 3 | 0.000 |
Why?
|
| Antibodies, Antinuclear | 1 | 1987 | 12 | 0.000 |
Why?
|
| Pyuria | 1 | 1985 | 1 | 0.000 |
Why?
|
| Urinary Tract Infections | 1 | 1985 | 29 | 0.000 |
Why?
|